Announcements Trials

Browse Landscape

Phase

Status

Recruiting 20 Unknown 14 Not yet recruiting 13 Active not recruiting 5 Completed 4 Terminated 3 Withdrawn 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Cyclophosphamide 129 Cisplatin 119 Radiotherapy 115 pembrolizumab 111 Carboplatin 97 Paclitaxel 96 Gemcitabine 96 Magnetic Resonance Spectroscopy 80 Nivolumab 76 Bevacizumab 76 Fluorouracil 74 Dexamethasone 73 Radiosurgery 66 Docetaxel 59 Rituximab 58 Leucovorin 57 Oxaliplatin 55 Capecitabine 55 Biopsy 53 Doxorubicin 52 fludarabine 51 Drug Therapy 45 durvalumab 44 Cytarabine 44 Etoposide 42 fludarabine phosphate 40 Pemetrexed 40 Radiation 39 atezolizumab 36 Surveys and Questionnaires 36

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × aflutinib × Clear all

NCT04958967 2025-03-14

Phase Ib Study of FURMONERTINIB in Patients with NSCLC Having Exon 20 Insertion Mutation

Allist Pharmaceuticals, Inc.

Phase 1 Withdrawn

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡